Quantifying Neural Stem Cell-Derived Extracellular Vesicle Uptake Using Imaging Flow Cytometry

Taylor J. Ellison, B. Jurgielewicz, S. Stice, Yao Yao
{"title":"Quantifying Neural Stem Cell-Derived Extracellular Vesicle Uptake Using Imaging Flow Cytometry","authors":"Taylor J. Ellison, B. Jurgielewicz, S. Stice, Yao Yao","doi":"10.33696/cancerimmunol.3.049","DOIUrl":null,"url":null,"abstract":"Nanomedicine, which includes nanoparticles and other nanomaterials for diagnosis and therapeutic delivery to treat numerous diseases, is making advances [1]. Utilizing engineered nanomaterials as delivery shuttles for therapeutics provides an opportunity to increase targeting specificity for treatments of certain disorders, as well as provide intrinsic benefits to cell systems of interest [2,3]. However, it is important to understand the functional properties of materials in pre-clinical studies. Proper selection of nanomaterials could be enhanced by recent studies in the field of cellular uptake of nanomaterials. The study of EVs is an expanding field within nanomedicine and are one such example of nanomaterials as a drug delivery shuttle. EVs are lipid-bound vesicles ranging in size from 40-1000 nm that mediate intercellular communication through shuttling nucleic acids, protein and lipids between cells. Once thought to be the secreted waste of cells, EVs have been engineered as drug delivery vectors due to multiple intrinsic benefits such as biocompatibility of genetic materials, therapeutic potentials, low immunogenicity and toxicity, ability to cross bio-barriers and for repeated dosing, various routes of administration [4-6]. Previous work from our group and others indicates that the therapeutic potential and Abstract","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33696/cancerimmunol.3.049","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Nanomedicine, which includes nanoparticles and other nanomaterials for diagnosis and therapeutic delivery to treat numerous diseases, is making advances [1]. Utilizing engineered nanomaterials as delivery shuttles for therapeutics provides an opportunity to increase targeting specificity for treatments of certain disorders, as well as provide intrinsic benefits to cell systems of interest [2,3]. However, it is important to understand the functional properties of materials in pre-clinical studies. Proper selection of nanomaterials could be enhanced by recent studies in the field of cellular uptake of nanomaterials. The study of EVs is an expanding field within nanomedicine and are one such example of nanomaterials as a drug delivery shuttle. EVs are lipid-bound vesicles ranging in size from 40-1000 nm that mediate intercellular communication through shuttling nucleic acids, protein and lipids between cells. Once thought to be the secreted waste of cells, EVs have been engineered as drug delivery vectors due to multiple intrinsic benefits such as biocompatibility of genetic materials, therapeutic potentials, low immunogenicity and toxicity, ability to cross bio-barriers and for repeated dosing, various routes of administration [4-6]. Previous work from our group and others indicates that the therapeutic potential and Abstract
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用成像流式细胞术定量神经干细胞来源的细胞外小泡摄取
纳米医学,包括用于诊断和治疗多种疾病的纳米粒子和其他纳米材料,正在取得进展。利用工程纳米材料作为治疗药物的递送载体,为提高某些疾病治疗的靶向特异性提供了机会,同时也为感兴趣的细胞系统提供了内在的好处[2,3]。然而,在临床前研究中,了解材料的功能特性是很重要的。最近在纳米材料的细胞摄取领域的研究可以提高纳米材料的正确选择。电动汽车的研究是纳米医学中一个不断发展的领域,是纳米材料作为药物传递穿梭体的一个例子。EVs是脂质结合囊泡,大小在40-1000 nm之间,通过在细胞间穿梭核酸、蛋白质和脂质介导细胞间通讯。曾经被认为是细胞的分泌废物,由于其遗传材料的生物相容性、治疗潜力、低免疫原性和毒性、跨越生物屏障的能力以及重复给药和多种给药途径等多重内在优势,ev已被设计为药物递送载体[4-6]。我们小组和其他人之前的工作表明,治疗潜力和摘要
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers Role of a Training Simulator for Kidney Biopsy and Tumor Removal Procedures in Complex Positioning Scenarios: The Key Challenges Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer. Enhancing the Efficacy of CAR-T Cell Therapy: A Comprehensive Exploration of Cellular Strategies and Molecular Dynamics. Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1